Cell Cycle / Checkpoint Control
Mre11 Blocking Peptide
|
イイネ！(0)
| 
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1035S | 100 μg | 16,000 | |
|
Mre11抗体製品一覧
| 使用目的 | |
| Mre11 (31H4) Rabbit mAb（#4847）の反応をブロックし、抗体の反応特異性を確認するために使用 |
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using Mre11 Antibody #4895 in the presence of control peptide (left) or Mre11 Blocking Peptide (right).
Mre11, originally described in genetic screens from the yeast Saccharomyces cerevisiae in which mutants were defective in meiotic recombination (1), is a central part of a multisubunit nuclease composed of Mre11, Rad50 and Nbs1 (MRN) (2,3). The MRN complex plays a critical role in sensing, processing and repairing DNA double strand breaks. Defects lead to genomic instability, telomere shortening, aberrant meiosis and hypersensitivity to DNA damage (4). Hypomorphic mutations of Mre11 are found in ataxia-telangiectasia-like disease (ATLD), with phenotypes similar to mutations in ATM that cause ataxia-telangiectasia (A-T), including a predisposition to malignancy in humans (5). Cellular consequences of ATLD include chromosomal instability and defects in the intra-S phase and G2/M checkpoints in response to DNA damage. The MRN complex may directly activate the ATM checkpoint kinase at DNA breaks (6).
-
Ajimura, M. et al. (1993) Genetics 133, 51-66.
-
D'Amours, D. and Jackson, S.P. (2002) Nat. Rev. Mol. Cell Biol. 3, 317-327.
-
van den Bosch, M. et al. (2003) EMBO Rep. 4, 844-849.
-
Theuissen, J.F. et al. (2003) Mol. Cell 12, 1511-1523.
-
Stewart, G.S. et al. (1999) Cell 99, 577-587.
-
Carson, C.T. et al. (2003) EMBO J. 22, 6610-6620.
